Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan
Open Access
- 1 June 2021
- journal article
- research article
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 54 (3) , 385-395
Abstract
No abstract availableKeywords
Funding Information
- Taipei Veterans General Hospital
This publication has 36 references indexed in Scilit:
- Predictors of hepatocellular carcinoma recurrence associated with the use of direct‐acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort studyCancer Medicine, 2019
- Liver Angiopoietin‐2 Is a Key Predictor of D e N ovo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct‐Acting AntiviralsHepatology, 2018
- Direct‐acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local‐regional therapy or liver transplant waitlist dropoutHepatology, 2018
- Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinomaJournal of Hepatology, 2016
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?Hepatology, 2014
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2012
- Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approachJournal of Hepatology, 2010
- Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosisHepatology, 2006
- Long-Term Survival and Pattern of Recurrence After Resection of Small Hepatocellular Carcinoma in Patients With Preserved Liver FunctionAnnals of Surgery, 2002